Exceptional Response to Pazopanib in a Patient with Urothelial Carcinoma Harboring FGFR3 Activating Mutation and Amplification

被引：24
|
作者：
Palma, Norma [1 ]
Morris, John C. [2 ]
Ali, Siraj M. [1 ]
Ross, Jeffrey S. [1 ,3 ]
Pal, Sumanta Kumar [4 ]
机构：
[1] Fdn Med, Cambridge, MA USA
[2] Univ Cincinnati, Inst Canc, Div Hematol Oncol, Cincinnati, OH USA
[3] Albany Med Coll, Dept Pathol & Lab Med, Albany, NY 12208 USA
[4] City Hope Comprehens Canc Ctr, Dept Med Oncol & Expt Therapeut, Duarte, CA 91010 USA
来源：
EUROPEAN UROLOGY | 2015年 / 68卷 / 01期
关键词：
D O I：
10.1016/j.eururo.2015.02.023
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：168 / 170
页数：4
相关论文
共 50 条
  • [1] Molecular mechanism in urothelial carcinoma with FGFR3 mutation.
    Liu, Huanhuan
    Zhang, Yanrui
    Lou, Feng
    Cao, Shanbo
    Wang, Huina
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16548 - E16548
  • [2] Sequential Response to FGFR3 Inhibition With Subsequent Exceptional Response to Atezolizumab in a Patient With FGFR3-TACC3 Fusion-Positive Metastatic Urothelial Carcinoma
    Nassar, Amin H.
    Lundgren, Kevin
    Kim, Jaegil
    Choueiri, Toni K.
    Sonpavde, Guru P.
    Kwiatkowski, David J.
    Bellmunt, Joaquim
    JCO PRECISION ONCOLOGY, 2018, 2 : 1 - 6
  • [3] Combination of Urine Cytology and FGFR3 Mutation for the Diagnosis of Urothelial Carcinoma
    Gao, L.
    Reddy, P. L.
    Joseph, L.
    Antic, T.
    Mueller, J.
    Khan, G.
    Torres, M.
    DeMay, R.
    Reeves, W.
    LABORATORY INVESTIGATION, 2012, 92 : 90A - 90A
  • [4] Combination of Urine Cytology and FGFR3 Mutation for the Diagnosis of Urothelial Carcinoma
    Gao, L.
    Reddy, P. L.
    Joseph, L.
    Antic, T.
    Mueller, J.
    Khan, G.
    Torres, M.
    DeMay, R.
    Reeves, W.
    MODERN PATHOLOGY, 2012, 25 : 90A - 90A
  • [5] FGFR3 mutation is not the initiating mutation in Urothelial Cell Cancer
    Ahmad, I.
    Iwata, T.
    Wu, X. R.
    Leung, H. Y.
    Sansom, O. J.
    BJU INTERNATIONAL, 2009, 103 : 18 - 18
  • [6] Validation of FGFR3 immunohistochemistry as a predictor of FGFR3 genetic alterations in urothelial carcinoma
    Lopez Del Campo, R.
    Mercader, C.
    Calderon, R.
    Albaiges, J.
    Ferrer-Mileo, L.
    Ribera-Cortada, I.
    Trias, I.
    Vilaseca, A.
    Rodriguez-Carunchio, L.
    VIRCHOWS ARCHIV, 2024, 485 : S172 - S172
  • [7] No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer
    Otto, Wolfgang
    Denzinger, Stefan
    Bertz, Simone
    Gaumann, Andreas
    Wild, Peter J.
    Hartmann, Arndt
    Stoehr, Robert
    INTERNATIONAL JOURNAL OF CANCER, 2009, 125 (09) : 2205 - 2208
  • [8] Mutation of FGFR3 in transitional cell carcinoma
    Sibley, K
    Kennedy, W
    Knowles, M
    BRITISH JOURNAL OF CANCER, 2001, 85 : 79 - 79
  • [9] Update on FGFR3 mutation and MRES phenotype in urothelial carcinogenesis
    Masson-Lecomte, A.
    Vordos, D.
    de la Taille, A.
    Neuzillet, Y.
    Radvanyi, F.
    Allory, Y.
    PROGRES EN UROLOGIE, 2013, 23 (02): : 96 - 98
  • [10] FGFR3 MUTATION ASSOCIATES WITH IMPROVED CANCER SPECIFIC OUTCOME IN UPPER TRACT UROTHELIAL CARCINOMA
    Sfakianos, John P.
    Cha, Eugene K.
    Kim, Philip H.
    Iyer, Gopa
    Hakimi, A. A.
    Scott, Sasinya N.
    Ramirez, Ricardo
    Hanrahan, Aphrothiti J.
    Rosenberg, Jonathan E.
    Ren, Qinghu
    Al-Ahmadie, Hikmat
    Dalbagni, Guido
    Bajorin, Dean F.
    Berger, Michael F.
    Bochner, Bernard H.
    Solit, David B.
    Coleman, Jonathan A.
    JOURNAL OF UROLOGY, 2014, 191 (04): : E920 - E920
12345